Bain Capital Life Sciences Investors, LLC
BOSTON, MA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.49B2026 Q3
Positions23
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.81.9%
Top Holdings
KLRA
Kailera Therapeutics
17.3%
HTFL
Heartflow
14.9%
ADRX
ADARx Pharmaceuticals
9.0%
ALKS
Alkermes
8.6%
NAMS
NewAmsterdam Pharma Co
6.2%
SVRA
Savara
6.1%
TARS
Tarsus Pharmaceuticals
5.8%
PHVS
Pharvaris N.V.
5.2%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.